Heart 2009;95:674-675
TECHNOLOGY AND GUIDELINES
Trans-catheter aortic valve implantation in the United Kingdom: NICE guidance
Dr Martyn Thomas, Guys and St Thomas NHS Foundation Trust, Lambeth Palace Road, London SE1 7EH, UK; Mttwins@aol.com
| The first 150 words of the full text of this article appear below. |
As the elderly population has grown, so symptomatic aortic stenosis has become an increasing problem with a poor prognosis if untreated.1 2 Trans-catheter aortic valve implantation (TAVI) has been designed to treat patients who would be at high risk during standard cardiac surgery. TAVI allows aortic valve implantation without the need for a sternotomy or cardiopulmonary bypass. The procedure may be performed from the femoral or trans-apical approach depending on the calibre of the peripheral vascular vessels and the device being used. The first human procedure was performed in 2002 and recently two devices have received a CE mark. The Edwards Sapien valve and the Corevalve are now available for commercial use in the United Kingdom. The Edwards valve is a balloon-expandable valve delivered either from the transfemoral or transapical (left 5th/6th intercostals space) approach, while the Corevalve is a self-expanding device which currently can only be delivered by the transfemoral
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
